CHMA News and Press, Chiasma Inc. From 06/27/19

In an update to investors, Chiasma (NASDAQ: CHMA ) announces that topline data from the Phase 3 OPTIMAL study evaluating Mycapssa (octreotide) in patients with acromegaly should be released by mid-Q3. More news on: Chiasma, Inc., Healthcare stocks news, Stocks on the move, Read mor...

WALTHAM, Mass., June 27, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that the company has been selected for inclusion in the broad-market ...

On track with U.S. Phase 3 CHIASMA OPTIMAL trial; data now expected by mid-Q3 2019 Target enrollment completed in ongoing Phase 3 MPOWERED™ trial; data expected in 2H 2020 WALTHAM, Mass., June 27, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopha...

Appoints pharma commercial veteran Raj Kannan as Chief Executive Officer Current CEO Mark Fitzpatrick to retain the role of President WALTHAM, Mass., June 05, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the...

Chiasma recently completed enrollment of its CHIASMA OPTIMAL Phase 3 clinical trial of octreotide capsules, the first potential oral somatostatin analog for the maintenance treatment of acromegaly Chiasma is developing octreotide capsules utilizing the company’s proprietary Transie...

Chiasma, Inc. (CHMA) Q1 2019 Earnings Conference Call May 09, 2019 05:00 PM ET Company Participants Glenn Garmont - IR Drew Enamait - VP of Finance & Administration and Principal Accounting Officer Mark Fitzpatrick - President, CEO, Secretary & Director William Ludlam -...

WALTHAM, Mass., May 09, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today reported financial results for the first quarter ended March 31, 2019 and provid...

WALTHAM, Mass., April 30, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that it will host a conference call and live audio webcast on Thursd...

Chiasma ( CHMA ) is a small clinical stage biopharmaceutical company that improves orphan drugs for rare diseases. The company uses its proprietary technology known as Transient Permeability Enhancer ((TPE)) to enhance the absorption of drugs through the intestinal walls of patients. By doin...

Gainers: CHMA   +4.3% . JMIA   +2.5% . PCB   +2.1% . FTEK   +1.9% . More news on: Chiasma, Inc., Jumia Technologies AG, Pacific City Financial Corporation, Stocks on the move, Read more ...